menu search

Celldex therapeutics presents positive data from barzolvolimab chronic urticaria program at eaaci 2023

– Data updates at EAACI 2023 continue to position barzolvolimab as a potential best-in-class addition...

June 10, 2023, 2:45 pm

Celldex therapeutics presents positive data from barzolvolimab phase 1b study in chronic spontaneous urticaria at aaaai 2023

– Rapid, profound and durable responses across multiple dosing groups with favorable safety profile observed—positioning barzolimab as a potential...

February 26, 2023, 2:00 pm

Celldex therapeutics announces multiple upcoming presentations of barzolvolimab data at ga²len global urticaria forum (guf) 2022

– Includes oral presentation for 1.5 mg/kg cold urticaria cohort – – Company to host webcast conference call on Tuesday, December 6 at 8:00 am E...

December 2, 2022, 2:31 pm

Celldex: barzolvolimab plus bispecific antibodies advancement

Proof of concept has been established in using barzolvolimab in treating Chronic spontaneous urticaria ...

July 14, 2022, 3:32 pm

Read how cantor views celldex therapeutics' barzolvolimab data

Celldex Therapeutics Inc's (NASDAQ: CLDX) shares closed almost 16% down on Friday after releasing Phase 1b study data of ...

July 5, 2022, 4:01 pm

Celldex (cldx) down on interim data from phase ib study in csu

Celldex (CLDX) posts interim data from the phase Ib study evaluating barzolvolimab in patients with mod...

July 4, 2022, 1:12 pm


Search within

Pages Search Results: